|
 Gilead Sciences Inc.'s (GILD) remdesivir, its coronavirus drug candidate, is most "beneficial" for Covid-19 patients who require supplemental oxygen but don't need mechanical ventilation, according to a study by the National Institute of Allergy and Infectious Diseases (NIAID)."Ultimately, the findings support remdesivir as the standard therapy for patients hospitalized with Covid-19 and requiring supplemental oxygen therapy," the report said, citing preliminary results from the randomized, controlled trial, published in The New England Journal of Medicine.Over a 10-day course, patients received the antiviral remdesivir intravenously and a placebo. The report showed that patients who received remdesivir had a shorter time to recovery than those who received placebo. The median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo."These findings support the use of remdesivir in this population, with the largest benefit observed among individuals who required oxygen supplementation but were not mechanically ventilated," said Merdad Parsey, Chief Medical Officer, at Gilead Sciences.Parsey added that Gilead expects results from its Phase 3 SIMPLE-Severe study, which is evaluating experimental remdesivir in a similar population of Covid-19 patients, to be published in the "near future".At the end of this month, Gilead expects to receive results from its Phase 3 SIMPLE-Moder
|
|
Florida family grieves as Trump spreads debunked conspiracy theory to attack MSNBC host The Washington PostGOP lawmaker calls on Trump to stop promoting Scarborough conspiracy theory: 'It will destroy us' | TheHill The HillTrump accuses TV presenter of murder as coronavirus deaths near 100,000 The Independent
|
|
 Twilio (TWLO) announced that it will provide the communications platform to power New York City's coronavirus contact tracing initiative sending shares up 7.5% on Friday.The cloud communications company said that New York City's Department of Information Technology & Telecommunications (DoITT) is planning to deploy a cloud-based contact center on Twilio Flex to call, message or email COVID-19 patients, educate them on the virus, and identify their close contacts through self-reporting. Terms of the deal weren't disclosed.The platform also provides messaging-based alerts using Twilio Voice, SMS, email or WhatsApp that prompt patients to fill out secure surveys on their symptoms. As governments around the world explore strategies to slow the spread of new coronavirus cases and safely reopen economies, public health departments have identified contact tracing as a step in the process."Throughout this pandemic, the ability for businesses and government agencies to quickly spin up and iterate ways to engage customers and constituents has never been more important," said George Hu, chief operating officer at Twilio. "New York City's contact tracing solution makes it possible for the city to connect with and support residents with COVID-19 and keep their known contacts safe and informed."Twilio stock jumped 7.5% to $208.62 on Friday. The value of the company's shares has almost tripled since mid-March after it posted strong sales figures as the coronavirus-related stay-at-hom
|
|
The plant-based meat substitute maker's CEO talks conquering China, encouraging consumer trials while the global meat supply chain is disrupted, and more.
|
|
Private Label